Clinical Trial Detail

NCT ID NCT03719131
Title Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Ipilimumab + Nivolumab + Rituximab

Age Groups: adult senior

No variant requirements are available.